[144] ResMed Inc. SEC Filing

Rhea-AI Filing Summary

ResMed insider notice to sell 3,000 common shares via Fidelity on 09/02/2025. The filing reports an aggregate market value of $812,310 for the proposed sale and states the company has 146,414,839 shares outstanding. The shares to be sold were acquired through an options grant (11/14/2018) covering 2,000 shares and restricted stock vesting on 11/11/2022 (204 shares) and 11/18/2022 (796 shares). The filer also disclosed three prior sales over the past three months by Brett Sandercock totaling 7,883 shares for gross proceeds of $2,087,372.17. The notice includes the standard representation that the seller is not aware of any undisclosed material adverse information.

Positive

• Filer provided detailed acquisition history including option grant and restricted stock vesting dates
• Disclosure includes broker, sale date, share counts, and aggregate market value, supporting transparency
• Form marked as LIVE, indicating an active filing

Negative

• Filer disclosed multiple sales in the past three months totaling 7,883 shares, which may be notable to some investors
• Filing does not include issuer financial results or context, limiting analysis to transactional data only

Insights

Financial Analyst

TL;DR: An insider has notified a proposed sale of 3,000 ResMed shares; prior near-term sales totaled 7,883 shares.

The filing documents a routine Rule 144 notice for sale of 3,000 common shares through Fidelity with an indicated market value of $812,310. Acquisition origins are specified: 2,000 from an options grant and 1,000 from restricted stock vesting events. The filer also reported three sales in the prior three months totaling 7,883 shares generating $2,087,372.17. This is a disclosure of intent to sell and does not provide company financial performance data.

Compliance / Corporate Governance Expert

TL;DR: The Form 144 appears to meet Rule 144 disclosure requirements and includes required seller representation.

The notice identifies the broker, sale date, share counts, acquisition dates, and payment nature, and it contains the signatory representation regarding absence of undisclosed material adverse information. The filing is marked LIVE and lists prior sales by the same individual in the past three months, fulfilling transparency expectations under transfer reporting rules.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	3000	812310.00	146414839	09/02/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/02/2025	Options Granted - 11/14/2018	Issuer			2000	09/02/2025	Cash
Common	11/11/2022	Restricted Stock Vesting	Issuer			204	11/11/2022	Compensation
Common	11/18/2022	Restricted Stock Vesting	Issuer			796	11/18/2022	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Brett Sandercock 9001 Spectrum Center Blvd. San Diego CA 92123	Common	06/02/2025	1000	243780.00
Brett Sandercock 9001 Spectrum Center Blvd. San Diego CA 92123	Common	07/01/2025	3883	997892.17
Brett Sandercock 9001 Spectrum Center Blvd. San Diego CA 92123	Common	08/01/2025	3000	845700.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the ResMed (RMD) Form 144 report?

The Form 144 reports a proposed sale of 3,000 common shares through Fidelity on 09/02/2025 with an aggregate market value of $812,310.

How were the 3,000 shares acquired according to the filing?

The filing shows 2,000 shares from an options grant dated 11/14/2018 and 1,000 shares from restricted stock vesting on 11/11/2022 (204) and 11/18/2022 (796).

What prior insider sales are disclosed in the Form 144?

The filer disclosed three sales by Brett Sandercock in the past three months: 06/02/2025: 1,000 shares ($243,780.00), 07/01/2025: 3,883 shares ($997,892.17), and 08/01/2025: 3,000 shares ($845,700.00).

Who is the broker named for the proposed sale?

The broker listed is Fidelity Brokerage Services LLC, 900 Salem Street, Smithfield RI 02917.

Does the filing state whether the seller knows any undisclosed material information?

Yes. By signing, the person represents they do not know any material adverse information about the issuer that has not been publicly disclosed.